American Well CORP 8-K filings

Amwell announced its second quarter 2026 financial results, showcasing total revenue at the top end of guidance, improved gross margin, and a narrowed net loss, while also raising its full-year revenue and Adjusted EBITDA outlook.

American Well Corporation announced a director reclassification to maintain balanced board classes as required by NYSE listing standards.

American Well Corporation announced the immediate resignation of Dr. Roy Schoenberg from its Board of Directors due to a new employment opportunity.

Dr. Peter Slavin is resigning from the American Well Corporation Board of Directors effective at the company's 2026 annual meeting, citing a move to the West Coast.

Amwell announced its fourth quarter and full year 2025 financial results, exceeding Q4 revenue guidance and outlining a path to positive cash flow from operations by Q4 2026.

American Well Corporation has renewed and expanded its strategic partnership with Elevance Health, Inc. for its LiveHealth Online digital care delivery platform through January 2029.

American Well Corporation has extended its Master Services Agreement and related provider agreements with Elevance Health, securing a multi-year partnership for its digital care platform and clinical services.

Amwell reported third-quarter 2025 financial results, surpassing revenue guidance and narrowing its full-year adjusted EBITDA loss outlook, driven by strategic execution and AI-powered platform adoption.

Amwell reported improved Adjusted EBITDA in Q2 2025, driven by strategic initiatives and cost alignment, despite a net loss and a downward revision to full-year revenue guidance.

American Well Corporation announced that its stockholders elected three Class II directors, ratified PricewaterhouseCoopers LLP as its independent auditor, and approved executive compensation at the 2025 Annual Meeting held on June 11, 2025.

Amwell reports Q1 2025 financial results, showing revenue of $66.8 million and progress towards cash flow breakeven in 2026.

Amwell announces the departure of Vaughn Paunovich and the appointment of Dan Zamansky as the new Chief Product and Technology Officer.

Amwell reports Q4 and full-year 2024 results, highlighting revenue, adjusted EBITDA improvements, and a path to positive cash flow in 2026.

Amwell divests its Amwell Psychiatric Care (APC) business to Avel eCare for approximately $21 million in cash at closing plus a potential earn-out payment, focusing on key growth initiatives and streamlining its product portfolio.

American Well Corporation appoints its CFO, Mark Hirschhorn, as Chief Operating Officer while two other executives, Kathy Weiler and Kurt Knight, will depart the company.

American Well Corporation's Board of Directors has approved a new inducement plan and granted substantial equity and cash-based awards to its incoming Chief Financial Officer, Mark Hirschhorn.

Amwell reported its Q3 2024 financial results, showing a net loss of $44 million and revised its full-year revenue and EBITDA guidance.

Amwell has announced the appointment of Mark Hirschhorn as its new Chief Financial Officer, effective October 21, 2024, following the resignation of Robert Shepardson.

American Well Corporation has amended its employment agreement with Chief Commercial & Growth Officer Kathy Weiler, outlining terms for her potential voluntary termination after June 1, 2025.

Amwell announced its second quarter 2024 financial results, highlighting progress in cost alignment and an improved adjusted EBITDA outlook for the year.

American Well Corporation executed a 1-for-20 reverse stock split of its Class A, B, and C common stock, effective July 10, 2024.

Amwell's board has approved a 1-for-20 reverse stock split to regain compliance with the NYSE's minimum share price requirement, effective July 10, 2024.

American Well Corporation's 2024 annual meeting saw the election of directors, ratification of the accounting firm, approval of executive compensation, and authorization of a reverse stock split.

American Well Corporation has appointed Ricky Goldwasser, a seasoned financial expert, to its Board of Directors, effective June 13, 2024.

Amwell's co-founder, Roy Schoenberg, is stepping down as co-CEO to become Executive Vice Chairman, while Ido Schoenberg will assume the role of sole CEO.

Amwell announced its first quarter 2024 financial results, highlighting progress in platform migration and sales transformation while reiterating its full-year guidance.

Amwell received a notice from the NYSE for not meeting the minimum share price requirement and plans to regain compliance through a reverse stock split.

Amwell announced its fourth quarter and full year 2023 financial results, highlighting progress on its new platform and providing financial guidance for 2024 and 2025.